Immunogenicity of the 3rd COVID-19 vaccine dose in Thai healthcare workers at Bamrasnaradura Infectious Diseases Institute

Active, not recruiting

• Conditions: Healthcare workers who received two doses of Sinovac; COVID-19 Vaccine; SARS-CoV-2; Antibody; Healthcare Workers; AstraZeneca; Pfizer

• Registration Number: TCTR20211005001
• Lead Sponsor: ational Research Council of Thailand (NRCT)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-10-05
• Study Completion: 2021-12-14
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 170

Inclusion Criteria

1. Age 18 years or more
2. Healthcare workers at Bamrasnaradura Infectious Diseases Institute
3. Received 2nd dose of Sinovac at least 21 days before
4. Eligible for ChAdOx1/AZD1222 COVID-19 vaccine
5. Informed consent for participation

Exclusion Criteria

Allergy to a component of ChAdOx1/AZD1222 COVID-19 Vaccine

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SARS-CoV-2 antibodies Before vaccination, 4 weeks post vaccination, 12 weeks post vaccination IgG (ELISA), Neutralizaing antibody (NeutraLISA)

Secondary Outcome Measures

Name	Time	Method
Cellular immunity Before vaccination, 4 weeks post vaccination, 12 weeks post vaccination T cell (Fluorospot), Memory B cell (Fluorospot),COVID-19 infection rate Before vaccination, 1 day post vaccination, 7 days post vaccination, 4 weeks post vaccination, 12 weeks post vaccination Symptom Assessment and confirmed with Real-time RT-PCR if suspected,Adverse events Before vaccination, 1 day post vaccination, 7 days post vaccination, 4 weeks post vaccination, 12 weeks post vaccination Patient report outcomes